| 0.57 -0.15 (-20.83%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.9 |
1-year : | 1.05 |
| Resists | First : | 0.77 |
Second : | 0.89 |
| Pivot price | 0.74 |
|||
| Supports | First : | 0.56 |
Second : | 0.47 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.76 |
| MA(100) : | 0.9 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 11.5  |
| RSI | RSI(14): 23.6 |
|||
| 52-week | High : | 1.87 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BFRI ] has closed below the lower bollinger band by 23.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BFRI ] is to continue within current trading range. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.78 - 0.79 | 0.79 - 0.79 |
| Low: | 0.56 - 0.57 | 0.57 - 0.57 |
| Close: | 0.56 - 0.57 | 0.57 - 0.58 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Thu, 18 Dec 2025
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - Sahm
Tue, 02 Dec 2025
Biofrontera submits sNDA to FDA for skin cancer treatment - Investing.com
Thu, 13 Nov 2025
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
Fri, 07 Nov 2025
Biofrontera (NASDAQ: BFRI) sells Xepi license to Pelthos for up to $10M; milestones - Stock Titan
Thu, 23 Oct 2025
Biofrontera (NASDAQ: BFRI) acquires U.S. Ameluz and RhodoLED rights, $11M funding - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 9.31e+006 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.751e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -47.3 % |
| Operating Margin | -89.9 % |
| Return on Assets (ttm) | -65 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.716e+007 % |
| Gross Profit (p.s.) | -38.8 |
| Sales Per Share | 330.56 |
| EBITDA (p.s.) | 4.12759e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.51 |
| Dividend | 0 |
| Forward Dividend | 32540 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|